keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant chemotherapy bladder cancer

keyword
https://www.readbyqxmd.com/read/28818551/adverse-pathology-after-neoadjuvant-chemotherapy-and-radical-cystectomy-the-role-of-adjuvant-chemotherapy
#1
William P Parker, Elizabeth B Habermann, Courtney N Day, Harras B Zaid, Igor Frank, R Houston Thompson, Matthew K Tollefson, Stephen A Boorjian, Lance C Pagliaro, R Jeffrey Karnes
BACKGROUND: The current guidelines do not recommend adjuvant chemotherapy (AC) for patients with adverse pathologic findings after neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) for bladder cancer. We sought to evaluate the association of AC with overall survival (OS) in these patients. MATERIALS AND METHODS: The National Cancer Database was used to identify patients with adverse pathologic findings (ypT3N0, ypT4N0, or ypTanyN1-N3) after NAC and RC for bladder cancer from 2006 to 2012...
July 22, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28815808/intravoxel-incoherent-motion-diffusion-weighted-imaging-in-assessing-bladder-cancer-invasiveness-and-cell-proliferation
#2
Fang Wang, Lian-Ming Wu, Xiao-Lan Hua, Zi-Zhou Zhao, Xiao-Xi Chen, Jian-Rong Xu
BACKGROUND: Nonmuscle-invasive bladder cancer (NMIBC, Stage T1 or lower) is treated with transurethral resection (TUR), while muscle-invasive bladder cancer (MIBC, Stage T2 or more) requires neoadjuvant chemotherapy before radical cystectomy. Hence, preoperative differentiation is vital. PURPOSE: To investigate whether intravoxel incoherent motion (IVIM) diffusion-weighted imaging (DWI) can differentiate NMIBC from MIBC and to assess whether there were correlations between IVIM parameters and the Ki-67 labeling index (LI)...
August 17, 2017: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/28803791/squamous-differentiation-predicts-poor-response-to-cisplatin-based-chemotherapy-and-unfavorable-prognosis-in-urothelial-carcinoma-of-the-urinary-bladder
#3
Akinori Minato, Naohiro Fujimoto, Tatsuhiko Kubo
OBJECTIVE: The efficacy of chemotherapy on UCSD is not known. This study was conducted to investigate the efficacy of cisplatin-based chemotherapy and prognosis of patients with UC with or without SD of the bladder. METHODS: Patients with invasive bladder cancer (clinical T3-4aN0M0) who were treated between March 2003 and March 2015 with 2 or 3 cycles of neoadjuvant chemotherapy followed by radical cystectomy were retrospectively evaluated. Treatment outcomes were compared for each pathologic type in UCSD and pure UC...
July 22, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28753879/robot-assisted-versus-open-radical-cystectomy-in-patients-receiving-perioperative-chemotherapy-for-muscle-invasive-bladder-cancer-the-oncologist-s-perspective-from-a-multicentre-study
#4
Andrea Necchi, Gregory R Pond, Marc C Smaldone, Sumanta K Pal, Kevin Chan, Yu-Ning Wong, Rosalia Viterbo, Guru Sonpavde, Lauren C Harshman, Simon Crabb, Ajjai Alva, Simon Chowdhury, Ugo De Giorgi, Sandy Srinivas, Neeraj Agarwal, Aristotelis Bamias, Jack Baniel, Ali-Reza Golshayan, Sylvain Ladoire, Cora N Sternberg, Linda Cerbone, Evan Y Yu, Joaquim Bellmunt, Ulka Vaishampayan, Gunter Niegisch, Syed Hussain, Daniel W Bowles, Rafael Morales-Barrera, Matthew I Milowsky, Christine Theodore, Dominik R Berthold, Srikala S Sridhar, Thomas Powles, Jonathan E Rosenberg, Matthew D Galsky
BACKGROUND: Little is known about the outcomes of robot-assisted radical cystectomy (RARC) compared to open radical cystectomy (ORC) combined with perioperative chemotherapy for muscle-invasive urothelial bladder cancer (UBC). OBJECTIVE: To evaluate surgical and oncological outcomes for RARC and ORC in multimodal treatment. DESIGN, SETTING, AND PARTICIPANTS: Data from 28 centres were collected for cystectomies performed between January 2000 and July 2013...
March 31, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28753857/the-impact-of-plasmacytoid-variant-histology-on-the-survival-of-patients-with-urothelial-carcinoma-of-bladder-after-radical-cystectomy
#5
Qiang Li, Melissa Assel, Nicole E Benfante, Eugene J Pietzak, Harry W Herr, Machele Donat, Eugene K Cha, Timothy F Donahue, Bernard H Bochner, Guido Dalbagni
BACKGROUND: The clinical significance of the plasmacytoid variant (PCV) in urothelial carcinoma (UC) is currently lacking. OBJECTIVE: To compare clinical outcomes of patients with any PCV with that of patients with pure UC treated with radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: We identified 98 patients who had pathologically confirmed PCV UC and 1312 patients with pure UC and no variant history who underwent RC at our institution between 1995 and 2014...
June 27, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28753837/absence-of-tumor-on-repeat-transurethral-resection-of-bladder-tumor-does-not-predict-final-pathologic-t0-stage-in-bladder-cancer-treated-with-radical-cystectomy
#6
Janet Baack Kukreja, Sima Porten, Vishnukamal Golla, Philip Levy Ho, Graciela Noguera-Gonzalez, Neema Navai, Ashish M Kamat, Colin P N Dinney, Jay B Shah
BACKGROUND: For patients with bladder cancer (BC) receiving neoadjuvant chemotherapy (NAC), complete pathologic absence of tumor (pT0) at radical cystectomy (RC) is associated with better survival. It is unclear if pT0 status can be attributed to the absence of residual disease (cT0) on transurethral resection of bladder tumor (TURBT) or to the effects of NAC. OBJECTIVE: To determine how often cT0 is associated with pT0 and identify preoperative and postoperative factors associated with survival...
January 18, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28753820/clinical-lymphadenopathy-in-urothelial-cancer-a-transatlantic-collaboration-on-performance-of-cross-sectional-imaging-and-oncologic-outcomes-in-patients-treated-with-radical-cystectomy-without-neoadjuvant-chemotherapy
#7
Marco Moschini, Alessandro Morlacco, Alberto Briganti, Brian Hu, Renzo Colombo, Francesco Montorsi, Igor Frank, Siamak Daneshmand, R Jeffrey Karnes
BACKGROUND: Data regarding clinical node metastases (cN+) in patients undergoing radical cystectomy (RC) are scarce. OBJECTIVE: To evaluate the performance of conventional imaging in detecting cN+ and analyze the impact of cN+ on survival among patients treated with RC without neoadjuvant chemotherapy (NAC). DESIGN, SETTING, AND PARTICIPANTS: Data from three independent centers of consecutive patients with bladder cancer treated with RC without NAC were analyzed...
November 23, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28753816/impact-of-high-risk-features-and-effect-of-neoadjuvant-chemotherapy-in-urothelial-cancer-patients-with-invasion-into-the-lamina-propria-on-transurethral-resection-in-the-absence-of-deep-muscle-invasion
#8
Michael J Metcalfe, James E Ferguson, Roger Li, Lianchun Xiao, Charles C Guo, Bogdan A Czerniak, Arlene Siefker-Radtke, Shanna M Pretzsch, Neema Navai, David J McConkey, Ashish M Kamat, Mathew Campbell, Colin Dinney
BACKGROUND: High-risk non-muscle-invasive bladder cancer (NMIBC) that invades into the lamina propria is frequently understaged and is associated with a risk of lymph node metastasis and death. OBJECTIVE: To identify high-risk features (HRFs) for NMIBC that may identify patients with poorer prognosis who may benefit from neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: We performed a single-center retrospective review of patients who underwent RC for NMIBC with invasion into the lamina propria between 1995 and 2013...
July 13, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28745580/pharmacogenomic-considerations-in-the-treatment-of-muscle-invasive-bladder-cancer
#9
Tahlita Cm Zuiverloon, Dan Theodorescu
Recent advances in next-generation sequencing techniques have greatly improved our understanding of the genomic alterations in bladder cancer. Cisplatin-based chemotherapy provides a viable treatment option in the neoadjuvant, adjuvant and metastatic setting in a selected group of patients, but chemoresistance is a major problem. The underlying mechanisms of treatment resistance are poorly understood and elucidating these pathways will subsequently lead to improved patient selection, less unnecessary drug-related toxicity, improved patient outcome and decreased healthcare costs...
August 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28743155/neoadjuvant-chemotherapy-prior-to-radical-cystectomy-for-muscle-invasive-bladder-cancer-with-variant-histology
#10
Malte W Vetterlein, Stephanie A M Wankowicz, Thomas Seisen, Richard Lander, Björn Löppenberg, Felix K-H Chun, Mani Menon, Maxine Sun, Justine A Barletta, Toni K Choueiri, Joaquim Bellmunt, Quoc-Dien Trinh, Mark A Preston
BACKGROUND: Neoadjuvant chemotherapy in pure urothelial bladder cancer provides a significant survival benefit. However, to the authors' knowledge, it is unknown whether this benefit persists in histological variants. The objective of the current study was to assess the effect of neoadjuvant chemotherapy on the probability of non-organ-confined disease and overall survival after radical cystectomy (RC) in patients with histological variants. METHODS: Querying the National Cancer Data Base, the authors identified 2018 patients with histological variants who were undergoing RC for bladder cancer between 2003 and 2012...
July 25, 2017: Cancer
https://www.readbyqxmd.com/read/28720358/prognostic-significance-of-neutrophilic-infiltration-in-benign-lymph-nodes-in-patients-with-muscle-invasive-bladder-cancer
#11
Sumanta K Pal, Anh Pham, Winston Vuong, Xueli Liu, Yulan Lin, Nora Ruel, Bertram E Yuh, Kevin Chan, Timothy Wilson, Seth P Lerner, David McConkey, Richard Jove, Wei Liang
BACKGROUND: Preclinical studies suggest that signal transducer and activator of transcription 3 (STAT3)-mediated recruitment of neutrophils to premetastatic tissue occurs prior to metastatic progression. OBJECTIVE: We sought to determine if neutrophilic infiltration in benign nodal tissue is associated with poor clinical outcome in patients with muscle-invasive bladder cancer. DESIGN, SETTING, AND PARTICIPANTS: Formalin-fixed, paraffin-embedded tissue was secured from 55 patients with muscle-invasive bladder cancer who had undergone cystectomy at our institution...
February 2017: European Urology Focus
https://www.readbyqxmd.com/read/28675174/landmarks-in-the-treatment-of-muscle-invasive-bladder-cancer
#12
REVIEW
Niyati Lobo, Chloe Mount, Kawa Omar, Rajesh Nair, Ramesh Thurairaja, Muhammad Shamim Khan
Muscle-invasive bladder cancer is an aggressive disease associated with high morbidity and mortality. Radical cystectomy is the mainstay of treatment and has evolved since the first reported cystectomy in 1887 to include pelvic lymph node dissection and the creation of increasingly sophisticated urinary diversions, such as neobladders and pouches, which enable patients to maintain continence. Pioneering work in the 1970s established the therapeutic activity of cisplatin in patients with bladder cancer and resulted in the introduction of cisplatin-based neoadjuvant chemotherapy, which led to the first improvement in survival outcomes in decades...
July 4, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/28674853/fdg-pet-ct-for-response-evaluation-of-invasive-bladder-cancer-following-neoadjuvant-chemotherapy
#13
E E Fransen van de Putte, E Vegt, L S Mertens, A Bruining, K Hendricksen, M S van der Heijden, S Horenblas, B W G van Rhijn
PURPOSE: We investigated the accuracy of FDG-PET/CT response identification following neoadjuvant or induction chemotherapy (NAIC) for invasive bladder cancer (BC) as to better select patients for radical cystectomy (RC). METHODS: Between 2010 and 2014, 37 cT1-4N1-3 BC patients received a FDG-PET/CT before and after NAIC followed by RC. Metabolic lymph node (LN) response was evaluated according to EORTC recommendations. Additionally, primary tumor response was evaluated for 23 patients by means of delayed pelvic imaging after forced diuresis...
July 3, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28650267/robotic-assisted-radical-cystectomy-versus-open-radical-cystectomy-for-management-of-bladder-cancer-review-of-literature-and-randomized-trials
#14
Kyrollis Attalla, Marissa Kent, Nikhil Waingankar, Reza Mehrazin
Among the many milestones in the last several decades in the management of muscle-invasive bladder cancer and high-risk nonmuscle-invasive bladder cancer including the extension of the standard lymph node dissection and the use of neoadjuvant chemotherapy, minimally invasive techniques have gained traction as an attractive option for radical cystectomy. Open radical cystectomy is plagued with high rates of perioperative and postoperative morbidity and mortality, and as robotic assistance has demonstrated benefits in other arenas of surgery and urology, the evolution of the approach to radical cystectomy has likewise incorporated robotic assistance...
June 2017: Future Oncology
https://www.readbyqxmd.com/read/28633191/-urothelial-cancer-update-on-systemic-treatment-options
#15
Günter Niegisch
Perioperative chemotherapy is likely to improve survival in both the neoadjuvant and the adjuvant setting. Therefore, it is an integral part of the modern treatment of patients with muscle-invasive urothelial bladder cancer. All patients who are suitable for cisplatin-based chemotherapy should be involved in a corresponding concept.Cisplatin-based combinations are standard regimens in the perioperative and palliative systemic treatment of urothelial cancer. Carboplatin is only an inferior substitute for "unfit" patients in the palliative treatment situation...
August 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28625029/-a-case-of-squamous-cell-carcinoma-in-bladder-diverticulum-producing-granulocyte-colony-stimulating-factor
#16
Koichi Uemura, Kazuhiro Namura, Susumu Umemoto, Osamu Matsubara, Koichi Udagawa
We report a rare case of squamous cell carcinoma (SCC) in bladder diverticulum producing granulocyte colony stimulating factor (G-CSF). A 59-year-old man complaining of hematuria and right hip pain was admitted with a large cancer in the bladder diverticulum. His laboratory data showed leukocytosis of 20,100/ μ l (neutrophils : 92%) with an elevated G-CSF of 76. 6 pg/ml in the peripheral blood. After neoadjuvant chemotherapy (gemcitabine and cisplatin), radical cystectomy was performed to normalize serum leukocytosis and G-CSF...
May 2017: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/28625005/dose-dense-mvac-prior-to-radical-cystectomy-a-real-world-experience
#17
Homayoun Zargar, Jay B Shah, Elisabeth E Fransen van de Putte, Kylea R Potvin, Kamran Zargar-Shoshtari, Bas W van Rhijn, Siamak Daneshmand, Jeff M Holzbeierlein, Philippe E Spiess, Eric Winquist, Simon Horenblas, Colin Dinney, Peter C Black, Wassim Kassouf
PURPOSE: Our primary endpoint was to assess pathological response rate (pT0N0 and ≤pT1N0) for patients with BCa treated with the accelerated or dose dense MVAC (ddMVAC) chemotherapy followed by radical cystectomy (RC) in this real-word multi-institutional cohort. MATERIALS AND METHODS: We retrospectively reviewed records of patients with urothelial cancer who underwent ddMVAC and RC at seven contributing institutions from 2000 to 2015. Patients with cT2-4a, M0 BCa were included...
June 17, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/28558988/association-of-distance-to-treatment-facility-with-survival-and-quality-outcomes-after-radical-cystectomy-a-multi-institutional-study
#18
Ahmed Q Haddad, Ryan Hutchinson, Erika L Wood, Gus Miranda, Boris Gershman, Jamie Messer, Robert Svatek, Peter C Black, Stephen A Boorjian, Jay Shah, Siamak Daneshmand, Yair Lotan
BACKGROUND: We sought to determine the effect of the travel distance on mortality and quality outcomes after radical cystectomy in a large multi-institutional cohort. PATIENTS AND METHODS: A total of 3957 patients who had undergone radical cystectomy for urothelial carcinoma at 6 North American tertiary care institutions were included. The association of travel distance with quality-of-care endpoints, 90-day mortality, and long-term survival were evaluated. RESULTS: The median patient age was 69 years (interquartile range, 61-76 years), and most patients were men (80%)...
May 10, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28545841/oncologic-outcomes-for-patients-with-residual-cancer-at-cystectomy-following-neoadjuvant-chemotherapy-a-pathologic-stage-matched-analysis
#19
Bimal Bhindi, Igor Frank, Ross J Mason, Robert F Tarrell, Prabin Thapa, John C Cheville, Brian A Costello, Lance C Pagliaro, R Jeffrey Karnes, R Houston Thompson, Matthew K Tollefson, Stephen A Boorjian
While it has been demonstrated that receipt of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) improves survival compared to RC alone, the driving factor for this benefit may be from patients with ypT0 status at surgery. Meanwhile, the implications of having residual urothelial carcinoma of the bladder (rUCB) at RC after NAC are less clear. We therefore evaluated whether survival differed between patients with rUCB at RC after NAC and stage-matched controls who underwent RC alone. Patients who underwent NAC + RC (n = 180) were matched to controls who underwent RC alone (n=324) on the basis of pT and pN stage, margin status, and year of RC...
May 22, 2017: European Urology
https://www.readbyqxmd.com/read/28500617/post-chemotherapy-pd-l1-expression-correlates-with-clinical-outcomes-in-japanese-bladder-cancer-patients-treated-with-total-cystectomy
#20
Daisuke Noro, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Toshiaki Kawaguchi, Chikara Ohyama
Programmed cell death ligand-1 (PD-L1) is a key target molecule of immunotherapy that is frequently overexpressed in bladder cancer. In the present study, we examined whether PD-L1 expression is associated with clinical outcomes in bladder cancer patients. We enrolled 102 bladder cancer patients treated with cystectomy at the Aomori Prefectural Hospital between April 2004 and May 2014. We conducted an immunohistochemical examination of PD-L1 expression using the SP142 assay. PD-L1 expression was scored at three diagnostic levels (0/1/2)...
June 2017: Medical Oncology
keyword
keyword
40909
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"